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complication whose impact on patients' health-related quality of life
is highly uncertain and has not been summarized to date. Objective:
The objective was to summarize the evidence base on SSI health
utility values reported in patient-level studies and decision models.
Methods: A systematic review of SSI utility values reported in
patient-level and decision modeling studies was carried out. Studies
in which utility values for SSI were either invoked (e.g., model-based
economic evaluations) or elicited (e.g., valuation exercises), or at
least one non–preference-based instrument was administered to
patients with SSI after open surgery were included. Mapping algo-
rithms were used, where appropriate, to calculate utilities from
primary data. Results were summarized narratively, and the quality
of the utility values used in the included modeling studies was
assessed. Results: Of 6552 records identiﬁed in the database search,
28 studies were included in the review: 19 model-based economicee front matter & 2015 Published by Elsevier Inc.
(ISPOR).
.1016/j.jval.2015.08.004
gheorghe@gmail.com.
ondence to: Adrian Gheorghe, Department of Globa
istock Place, London WC1H 9SH, UK.evaluations and 9 patient-level studies. SSI utility decrements
ranged from 0.04 to 0.48, of which 19 ranged from 0.1 to 0.3. SSI
utility decrements could be calculated for three patient-level studies,
and their values ranged from 0.05 (7 days postoperatively) to 0.124 (1
year postoperatively). In most modeling studies, SSI utilities were
informed by authors’ assumptions or by secondary sources. Con-
clusions: SSI may substantially affect patients’ health utility and
needs to be considered when modeling decision problems in surgery.
The evidence base for SSI utilities is of questionable quality and
skewed toward orthopedic surgery. Further research must concen-
trate on producing reliable estimates for patients without orthopedic
problems.
Keywords: health utility, surgical site infection, systematic review.
& 2015 Published by Elsevier Inc. on behalf of International Society for
Pharmacoeconomics and Outcomes Research (ISPOR).Introduction
Surgical site infection (SSI) is a postoperative complication with
incidence rates up to 27% in colorectal surgery [1]. SSI can
develop only if the surgical site is contaminated with micro-
organisms, which can originate either from the patient or from
the environment in the operating room. When the skin is incised,
the tissue is exposed to the ﬂora on the patient’s skin, mucous
membranes, and hollow viscera, which constitute the causative
agents of SSI in most cases [2]. Average European-wide SSI
incidence rates range from 0.7% in knee prosthesis to 9.7% in
colon surgery [3]. The burden of SSIs is even higher in low- and
middle-income countries than in high-income settings [4].
SSIs are associated with discomfort to the patient, excess
mortality, longer inpatient stays, and increased costs to the
health care system, the patient’s family, and the society at large
[5–9]. The additional cost attributable to SSI after colorectal
cancer alone has been estimated at £50 million per year in theUnited Kingdom [10]. Patients with SSI report reduced health-
related quality of life (HRQOL) compared to uninfected controls
[11], and patients with SSI may experience pain, insecurity, and
isolation over several months or even years [12].
SSI is preventable, although currently available technologies do
not allow 100% prevention [13]. Most proposed medical interven-
tions targeting SSIs address the known SSI risk factors, discussed
comprehensively in clinical guidelines issued by the US Centers for
Disease Control and Prevention [14] and UK’s National Institute for
Health and Care Excellence [15] together with SSI control strategies
pertaining to the preoperative (e.g., hair removal, antibiotic pro-
phylaxis, and bowel preparation), intraoperative (e.g., hand decon-
tamination and skin preparation), and postoperative phases (e.g.,
changing dressings and wound debridement) [16].
There is, however, limited evidence on the incremental cost-
effectiveness of SSI prevention measures compared with stand-
ard care (without the respective SSI control strategy). Such
evidence is necessary to reimburse technologies that representon behalf of International Society for Pharmacoeconomics and
l Health and Development, London School of Hygiene & Tropical
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interventions for health care decision making is in terms of
quality-adjusted life-years, which capture simultaneously the
effect of a condition on morbidity and mortality by combining
the length of life with a preference-based quality-of-life measure
in the form of health utility. There appears to be limited data to
inform quality-adjusted life-year calculations for interventions
targeting SSI [17,18]. Furthermore, SSI is a heterogeneous con-
dition that displays various degrees of severity [19] (e.g., super-
ﬁcial, deep, and organ/space SSI) and can occur after a wide range
of surgical procedures [20], with varying onset periods [21] and
associated management costs [7]. As such, the health utility of
patients with SSI can be expected to vary widely.
We conducted a systematic review of SSI health utility data to
1) identify and summarize the available information on the utility
decrement associated with having an SSI and 2) explore the
extent to which the type of SSI is reﬂected in available health
utility values. The ﬁndings are of interest primarily to policy-
makers with an interest in reducing SSI burden, to decision
analysts faced with modeling surgical outcomes, and to clinicians
aiming to incorporate SSI-related HRQOL measures in their
practice and research. The review is reported in accordance with
the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses statement [22].Methods
The systematic review was conducted according to a prespeciﬁed
protocol (available from the authors on request). Ethical approval
was obtained from the London School of Hygiene & Tropical
Medicine Research Ethics Committee (LSHTM Ethics Ref 8745).
Eligibility Criteria
The review included studies of any design in which utility values
for SSI were either invoked (e.g., model-based economic evalua-
tions) or elicited (e.g., valuation exercises), or at least one generic
or speciﬁc non–preference-based instrument was administered
to a cohort of patients with SSI (e.g., clinical trials and burden-of-
illness studies). All explicit SSI deﬁnitions were accepted. Only
those studies that investigated surgical wound outcomes in
patients undergoing open surgery were included. No language
restrictions were applied.
The following categories of studies were excluded: studies
that did not explicitly report utility values or HRQOL data for a
cohort of patients with SSI; studies that did not explicitly
investigate surgical wound outcomes; studies that had as a
primary outcome a composite of multiple surgical outcomes,
even if it included SSI or wound healing; studies looking at
nonsurgical wounds (e.g., burns, diabetic ulcers, and radiation
wounds) or other types of infections (e.g., systemic infections);
study protocols; and conference abstracts.
Information Sources
The following databases were searched from inception in April
2014: OVID MEDLINE and MEDLINE-In-Process, OVID EMBASE, ISI
Web of Knowledge (Science Citation Index), NHS Economic
Evaluation Database, and Wiley Health Economic Evaluation
Database. The search strategy (see Appendix 1 in Supplemental
Materials found at http://dx.doi.org/10.1016/j.jval.2015.08.004)
included two categories of search terms: terms associated with
wound infection, largely inspired by a previous systematic review
of clinical effectiveness of Wound-edge protection devices
(WEPDs) [23], and a range of terms relevant for HRQOL studies,
thus capturing both widely used generic preference-based multi-
attribute utility instruments, such as the EuroQol ﬁve-dimensional questionnaire (EQ-5D) [24], health utilities index 2
[25] and health utilities index 3 [26], Quality of Well-Being (QWB)
[27], and six-dimensional health state short form (derived from
the 36-item short-form health survey [SF-36]) [28], as well as non–
preference-based generic health status measures, such as the 12-
item short-form health survey [29] and SF-36 [30,31] health
surveys. The latter are of interest because their scores can be
mapped through statistical algorithms to preference-based meas-
ures and thus generate utility values [32].
Study Selection
The study selection process comprised three phases. In phase 1,
the titles and abstracts of returned articles were scanned against
the inclusion/exclusion criteria by two independent reviewers
(A.G. and H.D.). Articles demonstrating any of the exclusion
criteria were eliminated. If a decision could not be taken on the
basis of the title and abstract, the article was entered into phase
2. In phase 2, full-text versions of the articles resulting from
phase 1 were scanned against the inclusion/exclusion criteria by
two independent reviewers (A.G. and G.M.) and assigned a
category (A–E) and a subcategory (1–8), as follows: (A) the study
mainly reports primary data (i.e., collected speciﬁcally for the
study) on SSI utility or quality of life; (B) the study contains useful
primary or secondary (i.e., unoriginal data collected from already
published or other sources) SSI quality-of-life or utility data; (C)
the study may have useful economic information on aspects of
SSI care, but does not obviously fall into (A) or (B); (D) the study
discusses aspects related to SSI care, but neither (A) nor (B) above;
(E) the study has no relevance to SSI; (1) economic evaluation
(cost-minimization, cost-effectiveness, cost-utility, cost-beneﬁt);
(2) cost study; (3) effectiveness study with SSI quality-of-life or
health utility data relevant AND an SSI-free control group; (4)
effectiveness study other than (3); (5) methodological study on
aspects of economic assessment of SSI; (6) review of medical or
economic information; (7) other study, for example, purely
clinical content, survey of resources and facilities, survey of
utilization, estimate of economic burden, health policy, and
ﬁnancing; and (8) foreign language, to be translated. Studies in
categories A (1), A (3), B (1), B (3), C (1), and C (3) were carried
forward, whereas studies in foreign languages were translated
and reassessed. Agreement between the independent reviewers
(inclusion/exclusion) was measured using Cohen’s kappa [33],
and disagreements were resolved through discussion. In phase 3,
backward and forward reference searches were conducted for
articles retained in phase 2 to identify other potentially relevant
articles.
Data Extraction
The following data items were extracted from the articles
included after phase 3: study type; setting; type of surgery;
population; sample size (for primary studies); HRQOL instru-
ment(s) or utility measure used, as applicable (e.g., EQ-5D);
elicitation method; time of elicitation (e.g., 4 weeks after surgery);
source(s) for utility values; and utility values/HRQOL scores. Data
were extracted independently by two reviewers (A.G. and G.M.),
and disagreements were resolved through discussion. In the case
of relevant articles reporting primary data on SSI HRQOL scores
that could be mapped to health utilities using available statistical
algorithms, the authors were contacted with a request to make
available a partial, completely anonymized individual patient
data set with the detailed HRQOL scores necessary to conduct
the mapping, as per the published mapping algorithm. When
such primary data were not available, relevant mapping algo-
rithms relying on aggregate scores were sought in the literature
and, if available, were applied to derive utilities.
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The characteristics of the included studies and the utility values
relevant to patients with SSI were tabulated and summarized in a
narrative review. We devised a simple quality assessment frame-
work to rate the potential quality of the SSI (dis)utility estimates
used in the decision modeling studies, as follows: low quality—
utility values informed by author’s opinions or by secondary
references, that is, other modeling studies; medium quality—
utility values informed by a published systematic review or by
primary references, that is, HRQOL or preference elicitation stud-
ies; high quality—utility values informed by an updated system-
atic review or by a novel HRQOL/preference elicitation study.Results
The Preferred Reporting Items for Systematic Reviews and Meta-
Analyses ﬂow diagram is presented in Figure 1. In total 6552
articles were identiﬁed after the online database search. After
removing 1634 duplicates, 4918 articles were scanned for title/
abstract and 4834 were excluded (phase 1). In phase 2, 84 full-text
articles were reviewed and 55 studies were excluded for not
complying with the inclusion/exclusion criteria (see Appendix 2
in Supplemental Materials found at http://dx.doi.org/10.1016/j.
jval.2015.08.004). Cohen’s kappa was 0.69. No studies were iden-
tiﬁed through the reference list search. The study of Elliott et al.
[34] was excluded because it duplicated the previous publication
of the same research team [17], leaving 28 studies included in the
systematic review.
Of the 28 included studies, 19 were model-based economic
evaluations citing utility values that informed cost-utility analy-
ses (Table 1) and nine were patient-level studies that elicited
valuations of health status from patients with SSI using stand-
ardized questionnaires (Table 2). Most of the studies focused on
some form of orthopedic or spinal surgery, and one each referred
to cesarean delivery [35], open abdominal surgery [36], breast
reconstruction [37], and cardiac surgery [38].Fig. 1 – PRISMA ﬂow chart. HEED, Health Economic
Evaluation Database; NHS EED National Health Service
Economic Evaluation Database; PRISMA, Preferred Reporting
Items for Systematic reviews and Meta-Analyses.Model-Based Economic Evaluations
The utility values used in the decision models for the “No SSI”
and “SSI” health states are presented in Table 3. All 19 studies
provided values for the SSI health state, but in 3 studies [38–40]
the utility values for surgery without SSI were unclear; therefore,
an SSI utility decrement could be calculated only for 16 studies.
The SSI utility decrement ranged from values as low as 0.04 [41]
to as high as 0.48 [42]. The utility decrement ranged between 0.1
and 0.2 in eight studies [17,37,38,43–47] and between 0.2 and 0.4
in three studies [18,35,39].
Utility values were informed by a combination of published
literature and authors’ assumptions. Most of the models were of
low (12) and medium quality (6) in relation to the data sources
informing SSI utilities. Only one study elicited utility values from
a sample of 33 surgeons using a visual analogue scale [37]. Seven
studies relied on the authors’ assumptions [18,39,41,44–47]; nota-
bly, Brasel et al. [18] invoked the lack of published utility
estimates for wound treatment and used own assumptions. Of
the remaining studies, seven [17,35,39,42,46,48,49] referenced
other decision models and six [38,40,43,50–52] referenced
patient-level studies, but the appropriateness of the sources
was often unclear. For example, Bailey et al. [49] and Cranny
et al. [17] used a 0.1 SSI disutility informed by the review of Tengs
and Wallace [53], who had reported a 0.9 utility for an infection of
an artiﬁcial joint, informed, in turn, by a decision modeling study
[54] whose authors had assumed 0.9 quality-adjusted life-years
for a patient hospitalized for a year because of an infected
artiﬁcial joint. Similarly, the study of Fryback et al. [55] informed
utility estimates for revision arthroplasty [43] and for infection
after surgical treatment of closed fractures [42], but the study
itself reported time trade-off and SF-36 utility values for chronic
conditions and not for any type of surgical outcomes.
Only one decision modeling study used a systematic literature
review to inform health utility inputs: Cranny et al. [17] systemati-
cally reviewed the evidence on the effectiveness and cost-
effectiveness of glycopeptide antibiotics and identiﬁed one eco-
nomic evaluation that reported HRQOL information for SSI collected
using SF-36 [56]. Shepherd et al. [48] cited the Tufts Cost-
Effectiveness Registry as their SSI utility source, but did not disclose
the search strategy or the actual study(ies) informing the 0.642
value. Jensen et al. [41] reportedly conducted a literature review to
identify utility values, but no details were given and the SSI utility
estimate was ultimately informed by the authors’ assumptions.
Patient-Level Studies
Of the nine patient-level studies (Table 2), three referred to spinal
surgery [57–59], one each referred to hip [60], cardiac [61], and
orthopedic surgery [56], and three studies included patients
undergoing various interventions [11,36,62]. Seven studies
[11,36,57,59–62] predominantly enrolled patients older than 50
years. The sample sizes ranged from 32 [59] to 1301 [62], with ﬁve
studies [56–60] smaller than 100 patients. The number of patients
with SSI across the studies ranged from 13 [57] to 263 [62], with
ﬁve studies [56–60] reporting results from fewer than 30 patients
with SSI.
Five studies administered SF-36 [56–59,61], two studies used
the 12-item short-form health survey [11,60], and one study used
the three-level EQ-5D [36]. Other instruments included the
Oswestry Disability Index [57,58], the Numerical Rating Scale
[57,58], the General Health Questionnaire, and the Hospital
Anxiety and Depression Scale [62]. Three studies administered
the instruments less than a year after surgery [11,36,62], whereas
in the remaining studies [56–58,60,61] the assessments were
made after 1 year (Table 2). The detailed instrument scores are
presented in Appendix 3 in Supplemental Materials found at
http://dx.doi.org/10.1016/j.jval.2015.08.004.
Table 1 – Characteristics of model-based economic evaluations included in the systematic review.
Lead author, year Country Surgery type Hypothetical
cohort
characteristics
Time
horizon
Intervention(s) Comparator
Bailey 2011 [49] United States Hip and knee surgery Healthy adults with
average age 63 y
1 y Chlorhexidine bathing kit Standard care
Bhatnagar 2012 [44] United States Rib fracture ﬁxation Young adults with
blunt ﬂail chest
repaired within 5 d
of injury
Unclear Open reduction – internal ﬁxation Standard care
Brasel 1997 [18] United States Appendicectomy Adults given
preoperative
antibiotics
2 mo Primary closure; delayed primary
closure
Secondary closure
Courville 2012 [46] United States Hip and knee
arthroplasty
65-y-old adults with
end-stage hip or
knee osteoarthritis
for whom medical
management had
failed
1 y Screening for Staphylococcus aureus
þ preoperative nasal mupirocin
if positive; preoperative nasal
mupirocin for all
Standard care
Cranny 2008 [17] United Kingdom Hip arthroplasty Unclear Lifetime Cephalosporin prophylaxis;
vancomycin prophylaxis
Cephalosporin þ
vancomycin
prophylaxis
Cummins 2009 [47] United States Hip arthroplasty 68-y-old adults of
average health
Lifetime Antibiotic-impregnated bone
cement
Standard bone
cement
Jensen 2012 [41] United States Colon and rectal
surgery
Unclear 5 y Laparoscopic resection Open resection
Lee 2011 [35] United States Cesarean delivery Pregnant women
aged 27.1 y
1 mo Screening for S. aureus þ
decolonization
No screening,
standard
prophylaxis
Lee 2010 [40] United States Orthopedic surgery Median age 69 y 6 mo Vaccination for S. aureus No vaccination
Lee 2010 [38] United States Cardiac surgery Median age 65 y Lifetime Screening for S. aureus þ
decolonization
No screening,
standard
prophylaxis
Lee 2010 [52] United States Orthopedic surgery Median age 65 y Unclear Screening for S. aureus þ
decolonization
No screening,
standard
prophylaxis
Marinelli 2008 [43] Italy Total hip
arthroplasty
70-y-old patients Lifetime Cemented total hip arthroplasty Cementless total hip
arthroplasty
Merollini 2013 [50] Australia Total hip
arthroplasty
65-y-old adults Lifetime No antibiotic prophylaxis (AP); AP
þ antibiotic-impregnated
cement; AP þ laminated air
operating rooms
AP
continued on next page
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database of mapping studies [63], statistical algorithms are
available to map the SF-36 [64,65], the 12-item short-form health
survey [66,67], the General Health Questionnaire [68], the Hospital
Anxiety and Depression Scale [65], and the Numerical Rating
Scale [69,70] scores to the preference-based EQ-5D index, thus
deriving health utility values. We contacted by e-mail the authors
of the included patient-level studies and requested partial data
sets containing the patient group allocation (infected/control)
and the individual domain scores for the quality-of-life instru-
ments used so that we map the scores to utility values using
available statistical algorithms. For the randomized controlled
trial of wound-edge protection devices versus standard care
reported by Pinkney et al. [36], we used the EQ-5D domain scores
to calculate health utilities using the UK EQ-5D scoring algorithm
[71]. Four authors responded to our request [11,58,61,62], and the
remaining four failed to do so. Because none of the responding
authors could provide the required patient-level data to inform
the calculation of health utilities for infected and uninfected
patients, we used the SF-36 to EQ-5D mapping algorithm
informed by average domain scores [72] to derive utilities from
data reported by two of the included studies. This was not
possible for Jideus et al. [61], who did not report SF-36 post-
operative data for uninfected controls, for Mok et al. [59], who
reported only the four domains of the SF-36 physical component,
and Petilon et al. [58], who reported aggregate scores for the
mental and physical components.
The calculated SSI utility decrements ranged from 0.05 at 7
days postoperatively to 0.124 at more than 1 year after surgery
(Table 3), but differences among the long-term utilities (elicited at
least 1 month postoperatively) were small because all three
decrements fell within 0.10 to 0.12. Data collected using instru-
ments other than the SF-36 and the EQ-5D also suggest a negative
impact of SSI on HRQOL (see Appendix 3 in Supplemental
Materials).Discussion
Summary of Findings
We identiﬁed 29 SSI utility decrement estimates (of which one
was informed by the authors’ assumptions) ranging from 0.04 to
0.48, of which 19 estimates were between 0.1 and 0.3, thereby
conﬁrming that SSI is a clinically signiﬁcant complication asso-
ciated with mild to moderate disutility. Only four estimates came
from patient-level studies. Data from the only primary study
analyzing more than 50 SSIs [36] suggested a 0.12 utility decre-
ment at 30 days postoperatively. Included studies differed greatly
by surgery type, patient population, time frame (time horizon for
decision models and time of elicitation for patient-level studies),
and data sources or instruments informing the utility values.
Our review identiﬁed in the 19 included decision models poor
practices with little justiﬁcation. First, the vast majority of studies
did not apply principles of evidence-based medicine to identify
relevant utility values [73]. Furthermore, not all model parame-
ters were treated equally thoroughly when available evidence
was synthesized: for example, Lee et al. [52] conducted and
reported in detail a systematic review to identify transition
probabilities, but did not do so for utility values. Second, many
modeling articles sourced SSI utility values from references of
little or no relevance to SSI without justifying the choice of data
source, which potentially questions the validity of their research
ﬁndings. For example, the Selai and Rosser study [74], cited by
three modeling articles [38,40,52], was a pilot study conducted on
a sample of 23 patients in a UK general hospital, whose aims
were to assess the feasibility of administering the EQ-5D
Table 2 – Characteristics of patient-level studies included in the systematic review.
Lead author, year Country Surgery type Patient
characteristics
Sample size HRQOL instrument
administered
Time of
administration
postoperatively
Aboltins 2013 [60] Australia Hip arthroplasty Average age 65.8 y 95: 19 prosthetic joint
infections, 76
uninfected controls
Harris Hip Score; SF-12 12 mo
Falavigna 2011 [57] Brazil Lumbar arthrodesis Average age 61 y
(infection group)/
62 y (controls)
52: 13 deep wound
infections, 39
uninfected controls
Numerical Rating Scale
(NRS); Beck
Depression Index;
Oswestry Disability
Index (ODI); Hospital
Anxiety and
Depression Scale;
SF-36
Median 22 mo
(range 6–108 mo)
Jideus 2009 [61] Sweden Cardiac surgery Average age 69 y
(infection group)/
66 y (controls)
126: 84 surgical wound
infections, 42 controls
SF-36 Median 20 mo
(range 7–40 mo)
Mok 2009 [59] United States Spinal surgery Average age 54 y
(infection group)/
52 y (controls)
32: 16 deep wound
infections, 16
uninfected controls
SF-36 Unclear (“at the
most recent
follow-up visit or
by mail”)
Perencevich 2003
[11]
United States Nonobstetric
surgery
Average age 56 y
(infection group)/
57 y (controls)
267: 89 SSI patients, 178
uninfected controls
SF-12 Within 8 wk after
surgery
Petilon 2012 [58] United States Instrumented
spinal fusion
Average age 44 y 60: 30 deep wound
infections, 30
uninfected controls
ODI; SF-36; NRS 2 y
Pinkney 2013 [36] United
Kingdom
Open abdominal
surgery
Average age 66 y
(infection group)/
64 y (controls)
749: 184 patients with
superﬁcial SSI, 565
uninfected
EQ-5D-3L 7 and 30 d
Poulsen 1997 [62] Denmark Gynecologic,
orthopedic, and
general surgery
Patients older than
17 y, 56% older
than 50 y
1301: hospital cohort (58
surgical wound
infections, 648
uninfected), patient
cohort (263 surgical
wound infections, 767
uninfected)
General Health
Questionnaire; one
subjective well-being
question;
instrumental activity
of daily living
Median follow-up
5.5–10 mo
Whitehouse 2002
[56]
United States Orthopedic surgery Unclear 46: 23 patients with SSI,
23 uninfected controls
SF-36 1 y
EQ-5D-3L, three-level EuroQol ﬁve-dimensional questionnaire; HRQOL, health-related quality of life; SF-12, 12-item short-form health survey; SF-36, 36-item short-form health survey; SSI,
surgical site infection.
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Table 3 – SSI utility information reported in the included studies.
Lead
author,
year
Study
type
Surgery type “No SSI” utility
values
“SSI” utility values SSI utility
decrement
Cited sources
for utility
values
Primary source
for utility values
Quality
Bailey 2011
[49]
Decision
model
Hip and knee
surgery
0.84 0.756 0.084 [53] for SSI utility
decrement
Authors’
assumptions in
modeling study
[54], cited by
Tengs and
Wallace [53]
Low
Bhatnagar
2012 [44]
Decision
model
Rib fracture
ﬁxation
1 0.9 (wound infection) 0.1 Authors’
assumptions
Authors’
assumptions
Low
Brasel 1997
[18]
Decision
model
Appendicectomy 1 0.6 (0.7) for inpatient
(outpatient) treatment of an
open wound, an infected
wound, or both
0.3 and 0.4 Authors’
assumptions
Authors’
assumptions
Low
Courville
2012 [46]
Decision
model
Hip and knee
arthroplasty
0.68 (total knee
arthroplasty);
0.80 (total hip
arthroplasty)
0.54 (total knee arthroplasty);
0.64 (total hip arthroplasty)
0.14 and 0.16 [45,47] for SSI
health states
Authors’
assumptions in
modeling
studies [45] and
[47]
Low
Cranny
2008 [17]
Decision
model
Hip arthroplasty UK EQ-5D
population
norms adjusted
by age and sex
SSI utility decrement applied to
“No SSI” utilities
0.1 [53] for SSI utility
decrement
Authors’
assumptions in
modeling study
[54], cited by
Tengs and
Wallace [53]
Low
Cummins
2009 [47]
Decision
model
Hip arthroplasty 0.80 (total hip
arthroplasty)
0.64 (revision hip arthroplasty
due to infection)
0.16 Authors’
assumptions
of 20% utility
decrement
Authors’
assumptions
Low
Jensen 2012
[41]
Decision
model
Colon and rectal
resection
0.744 (open surgery) 0.7 0.044 Authors’
assumptions
for SSI health
state
Authors’
assumptions
Low
Lee 2010
[52]
Decision
model
Orthopedic surgery US population
norms of quality-
adjusted life
expectancy
0.642 Unclear [74,85] for SSI
health state
Primary studies
[74] and [85]
Medium
Lee 2010
[38]
Decision
model
Cardiac surgery 0.84 0.642 0.198 [74] for SSI health
state
Primary study [74] Medium
Lee 2010
[40]
Decision
model
Orthopedic surgery US population
norms of quality-
adjusted life
expectancy
0.642 Unclear [74] for SSI health
state
Primary study [74] Medium
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Lee 2011
[35]
Decision
model
Cesarean delivery 0.92 0.6 (inpatient treatment of SSI);
0.7 (outpatient treatment of
SSI)
0.22 and 0.32 [18] for SSI health
states
Authors’
assumptions in
modeling study
[18]
Low
Marinelli
2008 [43]
Decision
model
Total hip
arthroplasty
0.92 0.8 0.12 [55] for SSI health
state
Primary study [55] Medium
Merollini
2013 [50]
Decision
model
Total hip
arthroplasty
0.858 0.4 (deep infection) 0.458 [86] for deep
infection
Primary study [86] Medium
Michelson
2013 [39]
Decision
model
Surgical treatment
of unstable
ankle fractures
1 0.7 during ﬁrst year and 0.9
afterward (infection without
signiﬁcant sequelae); 0.7 in
all years (infection with
signiﬁcant sequelae)
0.1 and 0.3 [87] for infection
with
signiﬁcant
sequelae and
author’s
assumptions
for infection
without
sequelae
Authors’
assumptions in
modeling study
[87]
Low
Shepherd
2014 [48]
Decision
model
Midurethral sling
for female stress
incontinence
Unclear 0.642 Unclear [88] for SSI health
state
Unclear source
following
literature search
in database [88]
Low
Slobogean
2010 [42]
Decision
model
Surgical treatment
of closed
fractures
0.78 0.3 at 7 d; 0.34 at 30 d 0.44 and 0.48 [89] for SSI health
state
Unclear source
cited in
methodological
source [90], cited
in Kuntz et al.
[89]
Low
Slover 2006
[45]
Decision
model
Knee arthroplasty 0.68 0.532 0.148 Authors’
assumptions
for revision
arthroplasty
due to
infection
Authors’
assumptions
Low
Thoma 2003
[37]
Decision
model
Breast
reconstruction
0.87 0.76 if treated with antibiotics;
0.73 if requiring drainage
0.11 and 0.14 Elicited using
visual
analogue scale
from a sample
of 33 plastic
surgeons
Own study High
Wolf 2011
[51]
Decision
model
Hip arthroplasty 0.964 (patient-
derived); 0.913
(surgeon-
derived)
0.796 (patient-derived) and
0.750 (surgeon-derived) for
reinfection treated with
antibiotics; 0.632 (patient-
derived) and 0.533 (surgeon-
derived) for reinfection
treated with resection
0.168 and 0.332
(patient-derived)
0.163 and 0.380
(surgeon-derived)
[91] for SSI health
state
Primary study [91] Medium
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V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 1 1 2 6 – 1 1 3 71134instrument and to compare the EQ-5D utility values of a sample
of inpatients with those of the general population. Only 9 of the
23 patients had been admitted to a surgical ward, and it is not
clear from the article itself whether and how many of this study’s
patients actually experienced an SSI.
Interpretation of Findings
All included studies were consistent in suggesting that SSI may
pose a clinically signiﬁcant burden to patients undergoing vari-
ous types of surgery. The three patient-level studies for which
health utilities could be calculated were particularly consistent in
suggesting an SSI utility decrement close to 0.1. The only
exception was the 0.05 disutility estimate 7-day postoperatively
reported by Pinkney et al. [36] for laparotomy, but its relevance
may well be questioned given that the median time to onset for
most SSI types is in excess of 8 days [20,21].
Identifying a single reliable SSI disutility estimate remains
difﬁcult. First, few relevant patient-level preference studies are
available and we could ﬁnd no direct health utility elicitation
studies using preference-based methods such as time trade-off or
standard gamble. Second, the sample sizes of the available
studies were generally small, particularly in relation to the
number of reported patients with SSI. Third, the available SSI
decrement estimates may hardly be comparable, one reason
being that most patient-level studies were not explicit as to
whether patients in the SSI group had an ongoing SSI at the time
of the assessment. For studies with a follow-up period of 1 year or
more, this is unlikely. The three SSI utility decrements derived
from patient-level studies ranged from 0.1 to 0.124 and were
informed by utilities collected at different time points—30 days
[36], 1 year [56], and 22 months [57]—while the Centers for
Disease Control and Prevention deﬁnition [19] identiﬁes as SSI
infections occurring within 30 days postoperatively. As such,
these data may suggest that SSI disutility remains relatively
constant over time, but not knowing the exact SSI status of
patients at the time of elicitation in the respective studies
hinders any strong conclusion.
SSI heterogeneity also hinders comparability. Patient-level
studies referring to spinal surgery reported data on deep SSI
[57–59], the open abdominal surgery trial reported by Pinkney
et al. [36] explicitly identiﬁed superﬁcial SSIs, while Whitehouse
et al. [56] explicitly included both incisional and deep SSI across
11 types of orthopedic surgery. Given that deep SSIs take longer
to heal, require longer hospitalization, and are more costly to
manage than superﬁcial SSIs [75,76], these factors can affect
utility functions for patients with SSI.
No patient-level study in our review informed the SSI utility
estimates in any of the included decision models. The unavail-
ability of the relevant mapping algorithms at the time of conduct-
ing the model-based analyses may not hold as an explanation in
all cases. For example, the orthopedic decision models in our
review could have derived utilities from the SF-36 data for 11
surgical procedures, published in 2002 by Whitehouse et al. [56],
using the 2008 SF-36 domain score mapping algorithm [73].
Implications for Practice
Preventing SSI has the potential to substantially improve the
well-being of surgical patients. Our ﬁndings can inform future
economic evaluations of SSI preventative strategies to ensure
that only cost-effective technologies are reimbursed, thereby
minimizing the risk of wasteful resource deployment. Further-
more, SSI disutility is sufﬁciently relevant to warrant the consid-
eration of SSI as an adverse event when modeling broader
surgical decision problems [77]. More broadly, stronger adherence
to decision modeling good practice guidelines [78] is needed as
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 1 1 2 6 – 1 1 3 7 1135well as lending the same attention to summarizing the available
evidence on utility values that clinical effectiveness, transition
probabilities, and cost estimates usually receive.
Relation to Other Studies
To our knowledge, this is the ﬁrst systematic review to summa-
rize the available evidence on utility values associated with SSI.
Although little has been known about the HRQOL burden of SSI,
our ﬁndings are consistent with studies depicting the heteroge-
neous burden of SSI in terms of morbidity, inpatient stay, and
management costs [7,20].
Study Limitations
One limitation of our review is that many of the included studies
referred to health states following corrective surgery for arthro-
plasty infection. In such cases, patients are SSI-free at the time of
HRQOL/utility elicitation as a result of undergoing an additional
surgical procedure (revision arthroplasty) to eliminate deep
infection following initial arthroplasty; therefore, the associated
utility values refer to an outcome of SSI rather than to an ongoing
SSI. These are unequivocally deep infections and can, thus, be
ﬁrmly distinguished from incisional infections such as those
following cardiac or abdominal surgery. We felt, however, that
there was value in including this type of outcome given the high
incidence and serious consequences of orthopedic SSIs. The
comparability of SSI utility decrements identiﬁed in our review
may be problematic, as discussed above, and future reviews
focused on particular SSI types can provide more accurate
insights. Finally, pooling health state utility values using meta-
analytic techniques is becoming increasingly valuable for deci-
sion modelers [79–81], although clear methodological guidance is
lacking [77]. We were unable to combine the utility valuations in
a meta-analysis given the low number of primary studies iden-
tiﬁed and their heterogeneity [82]. Nevertheless, a large propor-
tion of utility values were informed by the authors’ assumptions
or had questionable relevance; therefore, a meta-analysis may be
viewed as inappropriate.
Further Research
UK’s National Institute for Health and Care Excellence currently
recommends for its technology appraisal reference case that the
HRQOL be measured directly by patients or their carers and that
these measurements be valued by a representative sample of the
general population using a choice-based method [83]. Our review
has identiﬁed few SSI valuations conforming to this norm,
pointing to a clear research gap. Given the complexity of SSI
manifestations, more studies are necessary to investigate the
HRQOL consequences of SSI, particularly of incisional SSI follow-
ing abdominal and thoracic surgery. This is even more crucial as
open surgery such as bowel surgery, cesarean section, and
coronary artery bypass graft record increased SSI incidence rates
compared with orthopedic surgery such as hip and knee pros-
thesis interventions [3,84]. Given that SSIs can heal from as little
as a few days to as long as 6 months, future SSI HRQOL and utility
elicitation studies should incorporate generous time frames and
report detailed results to allow modelers and decision makers to
judge the appropriateness of their estimates.Conclusions
Although the evidence base for SSI utility values is currently limited
and of questionable quality, the few available patient-level studies
are consistent in suggesting a clinically signiﬁcant impact of SSI on
patient health utility and quality of life. This information must beincorporated when estimating the value for money of prevention
and treatment technologies targeting SSI, as well as when evaluating
surgical technologies more broadly. Reliable utility estimates for
more types of SSI are needed given that research efforts to date
have focused on SSI following orthopedic surgery.Acknowledgments
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